Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

and Hsp-27 positive CTC counts, coupled with decreases in serum PSA and CA-125 levels in patients with prostate and ovarian cancer, markers that strongly suggest single agent anti-cancer activity for OGX-427," said Dr. Sebastien Hotte, Principal Investigator and a medical oncologist at Juravinski Cancer Centre, Hamilton, Ontario.

"We are very satisfied with the safety profile of OGX-427 to date in this trial and the early, strong indicators of anti-tumor and biological activity," said Scott Cormack, president and CEO of OncoGenex Pharmaceuticals.

About OGX-427

OGX-427 is designed to reduce production of Hsp27, a protein that is over-produced in response to many cancer treatments including hormone ablation therapy, chemotherapy and radiation therapy. Hsp27 production has been shown to inhibit cell death in tumor cells through a variety of mechanisms. OGX-427 is being evaluated in a Phase 1 clinical trial for the treatment of solid tumors including prostate, non-small cell lung, breast, ovarian, and bladder cancers. Like OGX-011, this product candidate has potential as a treatment in a broad number of cancers.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisen
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 “We are honored to ... said Ven Thangaraj, CEO of Radiant Sage. “We are ... taking the imaging corelab market to a different level. ... research organizations to efficiently and effectively manage the massive ... to be analyzed and read by trained physicians. Being ...
(Date:8/27/2014)... 2014 Research and Markets has ... Pulp & Paper Industry Report 2014" report to ... Pulp & Paper Industry Report 2014 is a professional ... global enzyme for pulp & paper industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/27/2014)... 2014 Riviera Beach, Florida based ... creation of the Sancilio Scientific Advisory Board (SSAB). ... philosophy of looking to nature for pharmaceutical advancements, ... are based on sound scientific data, analyses, expertise ... provides a vehicle for SCI to receive peer ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Remcom announces ... with new features for the biomedical industry. ... enhanced Biological Thermal Sensor, exclusive to the Bio-Pro version ... version of XFdtd, developed to calculate the biological effects ... has been added to all versions to expand engineers’ ...
Breaking Biology Technology:Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2Global Enzyme for Pulp & Paper Industry Report 2014 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 3
... Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biopharmaceutical ... therapeutics for,the treatment of solid and hematologic cancers, today ... upcoming conferences:, Rodman & Renshaw 10th Annual Healthcare ... Wednesday, November 12, 2008, 2:00 p.m. EST, ...
... MINNEAPOLIS, Nov. 3 ATS Medical, Inc.,(Nasdaq: ... state-of-the-art cardiac,surgery products and services, today announced ... development of the ATS Forcefield(TM),technology. The animal ... regarding the inhibition of platelet adhesion on ...
... Journal published,an article on October 29th describing the ... and featuring quotes from,President and founder Dr. Timothy ... Transfusions: New Efforts to Recycle Blood and Treat ... part of the "The Informed Patient",series written by ...
Cached Biology Technology:Sunesis to Present at Upcoming Conferences 2ATS Forcefield Anti-platelet Technology Continues to Demonstrate Positive Results 2ATS Forcefield Anti-platelet Technology Continues to Demonstrate Positive Results 3Wall Street Journal Highlights Blood Management, Strategic Healthcare Group LLC, and Dr. Timothy Hannon 2
(Date:8/28/2014)... most important crop-producing countries will be fully saturated with ... trends continue, according to a new study led by ... types can already be found in around half the ... advances at its current rate, scientists fear that a ... by pests within the next 30 years. , Crop ...
(Date:8/27/2014)... MADISON, Wis. The mechanical force that a single fungal ... seem vanishingly small, but it plays a heavy role in ... biology. In fact, it may not be too much of ... onto land without the ability to respond to the touch ... Jean-Michel An, a professor of agronomy at the University of ...
(Date:8/27/2014)... -- WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced that it ... units of common stock and warrants at a price ... million, prior to deducting underwriting discounts and commissions and ... warrants are immediately separable and will be issued separately.  ... consists of 2,000 shares of common stock and 2,000 ...
Breaking Biology News(10 mins):New study charts the global invasion of crop pests 2A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3
... major component in the spice turmeric, when combined with ... and neck cancer cell growth, researchers with UCLA,s Jonsson ... widely used in South Asian and Middle Eastern cooking, ... attributed to its anti-inflammatory effects. Previous studies have shown ...
... and tissues in our bodies grow, develop and interact ... microbial pathogens that invade our bodies and cause infectious ... the methods of culturing and studying human cells have ... impermeable surfaces. While such 2-D culturing and modeling efforts ...
... of Leeds plant scientists has uncovered a snapshot of evolution ... million years ago led flowers to make male and female ... week in the Proceedings of the National Academy of ... a perfect example of how diversity stems from such genetic ...
Cached Biology News:Major component in turmeric enhance effect of chemotherapy drug in head and neck cancer 2Major component in turmeric enhance effect of chemotherapy drug in head and neck cancer 3The world is not flat: Exploring cells and tissues in three dimensions 2The world is not flat: Exploring cells and tissues in three dimensions 3The world is not flat: Exploring cells and tissues in three dimensions 4100-million-year-old mistake provides snapshot of evolution 2
... Spring offers a large collection of ... fetal tissuea, cell lines, and mouse ... in pHD9 vector. The size of ... be from 200bp to 1000bp by ...
... The IDS Corticosterone kit is a competitive ... corticosterone in mouse or rat serum or ... sole, corticosteroid in rats and mice, and ... birds and reptiles. Most mammals produce both ...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Rabbit polyclonal to Nck alpha ( Abpromise for all tested applications). entrezGeneID: 4690 SwissProtID: P16333...
Biology Products: